New antidepressants: use in high-risk patients.
This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.